Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs

• Published in: Expert opinion on emerging drugs Vol. 25; no. 3; p. 319
• Main Authors: Lozupone, Madia, Solfrizzi, Vincenzo, D'Urso, Francesca, Di Gioia, Ilaria, Sardone, Rodolfo, Dibello, Vittorio, Stallone, Roberta, Liguori, Angelo, Ciritella, Chiara, Daniele, Antonio, Bellomo, Antonello, Seripa, Davide, Panza, Francesco
• Format: Journal Article
• Language: English
• Published: England 02.07.2020
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - physiopathology; Amyloid beta-Peptides - metabolism; Animals; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - pharmacology; Drug Development; Humans; Randomized Controlled Trials as Topic; tau Proteins - metabolism; solanezumab; gantenerumab; Alzheimer’s disease; ALZT-OP1; Monoclonal antibodies; BAN2401; aducanumab; GV-971; cognitive disorders; levetiracetam

Currently available Alzheimer's disease (AD) therapeutics are only symptomatic, targeting cholinergic and glutamatergic neurotransmissions. Several putative disease-modifying drugs in late-stage clinical development target amyloid-β (Aβ) peptide and tau protein, the principal neurophatological...